{
    "organizations": [],
    "uuid": "5ddad34d4f8c92ed5e391cf66e5601f1906d6d6c",
    "author": "",
    "url": "https://www.reuters.com/article/brief-alder-biopharmaceuticals-inc-to-pr/brief-alder-biopharmaceuticals-inc-to-present-new-phase-3-migraine-prevention-data-for-eptinezumab-idUSFWN1RV0KL",
    "ord_in_thread": 0,
    "title": "BRIEF-Alder Biopharmaceuticals Inc To Present New Phase 3 Migraine Prevention Data For Eptinezumab",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 50 PM / Updated 8 minutes ago BRIEF-Alder Biopharmaceuticals Inc To Present New Phase 3 Migraine Prevention Data For Eptinezumab Reuters Staff 1 Min Read \nApril 18 (Reuters) - Alder Biopharmaceuticals Inc: \n* ALDER BIOPHARMACEUTICALS INC - TO PRESENT NEW PHASE 3 MIGRAINE PREVENTION DATA FOR EPTINEZUMAB AT 70TH ANNUAL AMERICAN ACADEMY OF NEUROLOGY MEETING Source text for Eikon: Further company coverage:",
    "published": "2018-04-18T15:47:00.000+03:00",
    "crawled": "2018-04-18T16:04:08.005+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "biopharmaceuticals",
        "inc",
        "present",
        "new",
        "phase",
        "migraine",
        "prevention",
        "data",
        "eptinezumab",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "alder",
        "biopharmaceuticals",
        "inc",
        "alder",
        "biopharmaceuticals",
        "inc",
        "present",
        "new",
        "phase",
        "migraine",
        "prevention",
        "data",
        "eptinezumab",
        "70th",
        "annual",
        "american",
        "academy",
        "neurology",
        "meeting",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}